AI Score

Unlock

AbbVie Inc. (ABBV)

AI Score

Unlock

210.13

-1.83 (-0.86%)

At close: Mar 21, 2025, 3:59 PM

210.10

-0.02%

After-hours: Mar 21, 2025, 06:44 PM EDT

-0.86% (1D)

Bid	210
Market Cap	370.96B
Revenue (ttm)	56.34B
Net Income (ttm)	4.28B
EPS (ttm)	2.4
PE Ratio (ttm)	87.56
Forward PE	14.41
Analyst	Buy

Ask	210.2
Volume	6,187,156
Avg. Volume (20D)	5,813,313
Open	212.48
Previous Close	211.96
Day's Range	208.75 - 212.88
52-Week Range	153.58 - 218.66
Beta	0.60

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jan 2, 2013

Employees 55,000

Stock Exchange NYSE

Ticker Symbol ABBV

Website https://www.abbvie.com

Full Company Profile

Analyst Forecast

According to 19 analyst ratings, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $214.5, which is an increase of 2.08% from the latest price.

Stock Forecasts

Next Earnings Release

AbbVie Inc. is scheduled to release its earnings on Apr 25, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+3.39%

AbbVie shares are trading higher after multiple fi... Unlock content with Pro Subscription

1 month ago

+4.7%

AbbVie shares are trading higher following better-than-expected Q4 financial results.

News

1 day ago · seekingalpha.com

2025 Dividend Kings: Strong Run Continues

The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...

1 day ago · seekingalpha.com

My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys

February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77. Dividend income hit a new February record of $505, up 5% Y/Y driv...

1 day ago · fool.com

Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends

So, you want to invest in AbbVie (ABBV 0.14%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

2 days ago · fool.com

3 Dividend Stocks to Buy for Reliable Passive Income

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by ...

3 days ago · 247wallst.com

Only Have $500? 3 No-Brainer Stocks to Buy Right Now

Forget the old adage “it takes money to make money.

1 week ago · fool.com

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.

1 week ago · seekingalpha.com

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million up...